Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses emergence of 177Lu-PSMA-617 (LuPSMA) and overall significance of radiopharmaceuticals inmetastatic castration-resistant prostate cancer (mCRPC)
Data from the phase 3 VISION trial presented at the 2021 ASCO Annual Meeting showed that adding LuPSMA to standard of care (SOC) led to a nearly 40% reduction in the risk of death versus SOC alone in patients with progressive PSMA-positive metastatic mCRPC.
Analysis underscores value of piflufolastat F 18 in recurrent prostate cancer with low PSA levels
February 23rd 2023The data come from a sub-analysis of the pivotal phase 3 CONDOR trial of the PSMA-targeted radiopharmaceutical piflufolastat F 18 in men with suspected recurrence of prostate cancer.
2 Clarke Drive
Cranbury, NJ 08512